PubMed Health⌕ Search

PubMed · 11576523

Controlling postprandial hyperglycemia.

Abstract

A growing body of evidence indicates that measurements of postprandial glucose levels, in combination with glycosylated hemoglobin, are a more accurate predictor of metabolic abnormality than fasting or preprandial glucose levels for individuals with type 2 diabetes. Early identification of elevated postprandial blood glucose levels is an important step in predicting the onset of microvascular and macrovascular complications that can progress to full symptomatic diabetes. This article summarizes the research conducted to date on the diagnostic import of postprandial glucose and the parameters established for judging the need for treatment. When individuals cannot reach target glucose levels through diet and exercise, medical treatment is necessary. The article reviews a range of treatment options, including insulin secretagogues, insulin sensitizers, antiabsorptive agents, weight reduction agents, and insulin and combination medical therapy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R E Ratner. 2001-09-20. Controlling postprandial hyperglycemia.. https://doi.org/10.1016/s0002-9149(01)01834-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.

Inhibitors of integrin alphavbeta3 have been implicated in the treatment of a variety of diseases, including tumor metastasis, neovascularization, osteoporosis, and rheumatoid arthritis. It is therefore desirable to develop new types of small molecule inhibitors of integrin alphavbeta3. Here we describe the discovery of novel classes of small molecule inhibitors, via structure-based virtual screening, that target the ligand binding site of integrin alphavbeta3. Application of the docking procedure for screening of a commercially available compound database resulted in a 1774-fold reduction in the size of the screening set (88695 to 50 compounds) and gave a hit-rate of 14% upon biological evaluation (IC50 value ranging from 30 to 200 microM). The best hit, compound 37, 3,4-dichloro-phenylbiguanide, showed inhibitory activity, in a time- and dose-dependent manner, in both cell motility and angiogenesis assays. Based on the best hit, compound 37, a more effective derivative compound 62 has been identified. Furthermore, molecular graphics analyses of a series of substituted phenylbiguanides were carried out to predict the binding mode between the active compounds and integrin alphavbeta3. Our results indicate that the substituted phenylbiguanides might be involved in the inhibition of bivalent cation-mediated ligand binding of integrin alphavbeta3.

Biguanides↗